BioSpace News Archive

Benson Hill Biosystems, a crop improvement company unlocking the natural diversity of plants, and RiceTec, a leader in hybrid rice seed technologies, announced prior to the kick off of the Plant and Animal Genome Conference at Shenzhen, China, the licensing agreement for the use of Benson Hill’s technologies as part of RiceTec’s rice research and development operations.

New survey reveals nearly three in four Americans say that talking to a close family member about cognitive decline would be challenging

CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019 in New York, NY.

Sierra Oncology, Inc. is holding an analyst and investor event featuring distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit, to discuss clinical findings and possible next steps for its oral, highly selective Chk1 inhibitor, SRA737.

Armata Pharmaceuticals, Inc. announced that the company continues to strengthen its intellectual property portfolio with the allowance of two patents by the European Patent Office and one allowance by the Canadian Intellectual Property Office.

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CFO, David Snyder, will give a company presentation on Tuesday, June 4th, 2019 at 3:40-4:00 pm MDT at the LD Micro 9th Invitational Conference.

Antibe Therapeutics Inc. is pleased to announce the lead indication for its second pipeline drug, ATB-352, a potent and non-addictive analgesic for the treatment of severe pain.

Ablexis grants rights to use the AlivaMab™ Mouse platform for research, development and potential commercialization of antibodies

Non-Browning Romaine lettuce demonstrates improved shelf life, reducing food waste and is not subject to regulation as a product produced through genetic engineering by the USDA

Seattle Genetics, Inc. and Astellas Pharma Inc. announced that data from the first cohort of a pivotal phase 2 clinical trial known as EV-201 demonstrated that the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44 percent.